Sign in with Google. Opens in new tab
bullish
Alphamab (康宁杰瑞) IPO: Thoughts on Base-Line Valuation
587 Views14 Oct 2019 07:16
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange. In our previous...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 2-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »Loading
Top Unpaywalled Insights
More »- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM01 Dec 2019
- Alphamab (康宁杰瑞) IPO: You Will Likely Be Zeroed29 Nov 2019
- Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates18 Nov 2019
- Alphamab (康宁杰瑞) IPO: Thoughts on Base-Line Valuation14 Oct 2019
- Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi30 Jul 2019
- Alphamab (康宁杰瑞) IPO: Strong R&D Capability and Innovative Platforms24 Jul 2019
x